

Australia approves aesthetic neurotoxin developed by US-based cosmetic firm Evolus

27 January 2023 | News

Australia among the largest countries in the world for aesthetic neurotoxins



Evolus, Inc., a US-based performance beauty company with a customer-centric approach focused on delivering breakthrough products, has announced that the Australian Therapeutic Goods Administration (TGA) has provided regulatory approval for Nuceiva (prabotulinumtoxinA), a neurotoxin dedicated exclusively to aesthetics. Nuceiva was approved for the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients. Glabellar lines are the vertical lines between the eyebrows seen at maximum frown.

Cosmetic neurotoxins are injectable solutions made with a neurotoxin known as botulinum toxin type A. This type of botulinum toxin works by blocking nerve impulses to facial muscles and causing them to relax, thereby smoothing wrinkles formed by frowning, squinting, and other facial expressions.

According to David Moatazedi, President and Chief Executive Officer, Evolus, "This approval is the latest example of our commitment to broaden our international presence, which is a key component to reaching our aspiration of \$500 million in total revenue by 2028."

Evolus plans to launch Nuceiva in Australia during the second half of 2023 after commencing additional launches in Europe, beginning with Germany and Austria, in the first half of 2023. In addition to Great Britain, Nuceiva is also commercially available in Canada.